During the course of blood bank screening, 1.5% of """"""""normal"""""""" donors have been found to have an elevated ALT. These donors will continue to be identified as part of a protocol. In order to determine the significance of these abnormalities donors will be recalled for complete history and physical with emphasis on any non-viral causes for elevated transaminase. In addition, their ALT will be monitored monthly for six months and periodically thereafter. They will also undergo liver-spleen scan, gall bladder x-rays and ultrasound, upper GI and, pending their course and separate informed consent, they may undergo liver biopsy. Their evaluation will be similar to that of patients who develop chronic NANB hepatitis after transfusion.
